VEGFA and ovarian carcinoma: Although platinum-based chemotherapy combinations are the primary treatment for epithelial ovarian cancer, recent years have seen the introduction of targeted therapies, including humanized monoclonal antibody against vascular endothelial growth factor (VEGF) bevacizumab, inhibitors of poly (ADP-ribose) polymerase (PARPi), and antifolate receptor alpha antibody drug conjugates, expanding the pharmacologic landscape.